In 2024, Spain leads globally in respiratory system medicine sales, reaching $2.83 billion PPP. Italy follows with $2.38 billion, while Croatia, Japan, and Belgium trail with $1.02 billion, $0.9893 billion, and $0.7977 billion, respectively. The Czech Republic, Chile, Mexico, Austria, Denmark, and Luxembourg report smaller sales figures, with Luxembourg at the lowest with $0.0237 billion.
The year-on-year analysis from 2023 shows notable growth for Austria (10.46%), Luxembourg (7.91%), and Italy (6.83%), while Japan and Mexico experienced declines of -2.04% and -2.36%, respectively. This increasing sales trajectory illustrates a positive CAGR trend for Italy, Croatia, Belgium, and Austria over the last 5 years.
Future trends to watch for in the global respiratory system medicine market include potential growth in emerging markets, driven by increasing urbanization and pollution. Innovations in treatments and rising healthcare expenditure are expected to bolster sales, while ongoing economic challenges may pose risks for certain countries.
Top countries in Respiratory System Medicine Sales by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Spain | 2,830 | 2023 | +2.43% | +6.04% | View data |
| 2 | 2 Italy | 2,380 | 2023 | +3.14% | +6.83% | View data |
| 3 | 3 Croatia | 1,020 | 2023 | +2.84% | +2.99% | View data |
| 4 | 4 Japan | 989.3 | 2023 | -1.42% | -2.04% | View data |
| 5 | 5 Belgium | 797.7 | 2023 | -20.48% | +3.29% | View data |
| 6 | 6 Czech Republic | 668.4 | 2023 | +10.63% | +1.62% | View data |
| 7 | 7 Chile | 557.8 | 2023 | +2.86% | +1.27% | View data |
| 8 | 8 Mexico | 547.3 | 2023 | -2.96% | -2.36% | View data |
| 9 | 9 Austria | 401.3 | 2023 | +9.58% | +10.46% | View data |
| 10 | 10 Denmark | 344.7 | 2023 | +2.32% | +3.23% | View data |
